The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer

por El Ansari, Rokaya, Alfarsi, Lutfi, Craze, Madeleine L., Masisi, Brendah K., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Publicado 2020

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer

por Alfarsi, Lutfi H., El Ansari, Rokaya, Craze, Madeleine L., Masisi, Brendah K., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Publicado 2020

Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer

por Alfarsi, Lutfi H., El Ansari, Rokaya, Masisi, Brendah K., Parks, Ruth, Mohammed, Omar J, Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Publicado 2020

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer

por Alfarsi, Lutfi H., El-Ansari, Rokaya, Craze, Madeleine L., Masisi, Brendah K., Mohammed, Omar J., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Publicado 2020

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer

por Alfarsi, Lutfi H., El Ansari, Rokaya, Craze, Madeleine L., Mohammed, Omar J., Masisi, Brendah K., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Publicado 2021

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer

por Masisi, Brendah K., El Ansari, Rokaya, Alfarsi, Lutfi, Craze, Madeleine L., Jewa, Natasha, Oldfield, Andrew, Cheung, Hayley, Toss, Michael, Rakha, Emad A., Green, Andrew R.
Publicado 2021